Welcome to LookChem.com Sign In|Join Free
  • or
Benzoic acid, 3-methoxy-4-(methoxymethoxy)-, ethyl ester is a complex organic compound with the chemical formula C12H16O5. It is an ester derivative of benzoic acid, featuring a 3-methoxy group and a 4-methoxymethoxy group attached to the benzene ring. The ethyl ester group is connected to the carboxylic acid moiety, enhancing its solubility in organic solvents. Benzoic acid, 3-methoxy-4-(methoxymethoxy)-, ethyl ester is known for its potential applications in the pharmaceutical and chemical industries, particularly as an intermediate in the synthesis of various drugs and other organic compounds. Its unique structure also makes it a subject of interest in research for its possible biological activities and chemical properties.

5942-32-5

Post Buying Request

5942-32-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5942-32-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 5942-32-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,9,4 and 2 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 5942-32:
(6*5)+(5*9)+(4*4)+(3*2)+(2*3)+(1*2)=105
105 % 10 = 5
So 5942-32-5 is a valid CAS Registry Number.

5942-32-5Relevant academic research and scientific papers

MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF

-

Page/Page column 79; 89, (2017/02/24)

Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 5942-32-5